Prashant Kumar, Chief Scientific Officer at Datar Cancer Genetics, shared a post on LinkedIn about a paper published in The Journal of Liquid Biopsy:
“Liquid Biopsy has TRANSFORMED the landscape of Cancer Treatment and Management. It stands as one of the most revolutionary discoveries in Oncology, with a profound Impact on Early Diagnostics, Prognostication, minimal residual disease (MRD) assessment, Disease Monitoring, and the identification of resistance mechanisms.
Our recent Manuscript highlights how Liquid Biopsy can serve as powerful tool to guide clinical decision-making-whether it is treatment escalation or de-escalation through real-time insights. The data we presented exemplifies the strength of collaborative science and its direct relevance to patient care.
The remarkable efforts of Datar Cancer Genetics Limited, together with the visionary leadership of Sewanti Limaye and Rajan Datar and the other brights minds both clinical and researchers Aditya Shreenivas, Darshana Patil, Janani Sambath, Irene A George, Anjali Parab, Aakriti Datta, Punita Jain, Shambhavi Singh, Chetan Madre, Pritam Kataria, Darshit Shah, Niyati Shah, their immense contributions have made it possible to generate real-world evidence that highlights the transformative role of Liquid Biopsy in Cancer Care!
This work will be a true delight for readers, offering deep insights into the perspective and applications of Liquid Biopsy, and showcasing it potential to shape decision making in routine clinical practice.”
Title: Liquid biopsy- A pivotal test to help navigate clinical decisions at a precision center in India!
Authors: Sewanti Limaye, Aditya Shreenivas, Darshana Patil, Janani Sambath, Irene A. George, Anjali Parab, Aakriti Datta, Punita Jain, Shambhavi Singh, Chetan Madre, Pritam Kataria, Darshit Shah, Niyati Shah, Ruturaj Deshpande, Rajan Datar, Prashant Kumar
Read the full article.
More posts featuring Prashant Kumar on OncoDaily.